Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.
2.
3.

Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.

Biswas DK, Iglehart JD.

J Cell Physiol. 2006 Dec;209(3):645-52. Review.

PMID:
17001676
4.

In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer.

Kurbel S.

Tumour Biol. 2013 Feb;34(1):1-7. doi: 10.1007/s13277-012-0602-1. Epub 2012 Dec 4. Review.

PMID:
23208673
5.

Studies of epidermal growth factor receptor inhibition in breast cancer.

Bundred NJ, Chan K, Anderson NG.

Endocr Relat Cancer. 2001 Sep;8(3):183-9. Review.

6.

HER2 as a prognostic factor in breast cancer.

Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A.

Oncology. 2001;61 Suppl 2:67-72. Review.

PMID:
11694790
7.

Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.

Skalova A, Ryska A, Kajo K, Di Palma S, Kinkor Z, Michal M.

Histopathology. 2005 Jan;46(1):43-9. Review.

PMID:
15656885
8.

Triple-negative breast cancer: an unmet medical need.

Hudis CA, Gianni L.

Oncologist. 2011;16 Suppl 1:1-11. doi: 10.1634/theoncologist.2011-S1-01. Review.

9.

Breast cancer precursors revisited: molecular features and progression pathways.

Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS.

Histopathology. 2010 Aug;57(2):171-92. doi: 10.1111/j.1365-2559.2010.03568.x. Epub 2010 May 24. Review.

PMID:
20500230
10.

Triple negative breast cancer: from molecular portrait to therapeutic intervention.

Carotenuto P, Roma C, Rachiglio AM, Botti G, D'Alessio A, Normanno N.

Crit Rev Eukaryot Gene Expr. 2010;20(1):17-34. Review.

PMID:
20528735
11.

Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?

Burness ML, Grushko TA, Olopade OI.

Cancer J. 2010 Jan-Feb;16(1):23-32. doi: 10.1097/PPO.0b013e3181d24fc1. Review.

PMID:
20164687
12.

[Basal-like breast cancer: a review].

Treilleux I, Morellon-Mialhe B.

Ann Pathol. 2009 Jun;29(3):180-6. doi: 10.1016/j.annpat.2009.04.001. Epub 2009 Jun 12. Review. French.

PMID:
19619822
13.

A new model for ductal carcinoma in situ suggests strategies for treatment.

Gullick WJ.

Breast Cancer Res. 2002;4(5):176-8. Epub 2002 Jul 19. Review.

14.
15.

Stages on the way to breast cancer.

Going JJ.

J Pathol. 2003 Jan;199(1):1-3. Review.

PMID:
12474219
16.

Molecular evolution of breast cancer.

Simpson PT, Reis-Filho JS, Gale T, Lakhani SR.

J Pathol. 2005 Jan;205(2):248-54. Review.

PMID:
15641021
17.

Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.

Reyes C, Jorda M, Gomez-Fernández C.

Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):283-6. doi: 10.1097/PAI.0b013e31826a277e. Review.

PMID:
22935826
18.

Basal-like breast carcinoma: a phenotypically distinct entity.

Haupt B, Ro JY, Schwartz MR.

Arch Pathol Lab Med. 2010 Jan;134(1):130-3. doi: 10.1043/1543-2165-134.1.130. Review.

PMID:
20073617
19.

Triple negative breast cancers: clinical and prognostic implications.

Dawson SJ, Provenzano E, Caldas C.

Eur J Cancer. 2009 Sep;45 Suppl 1:27-40. doi: 10.1016/S0959-8049(09)70013-9. Review.

PMID:
19775602
20.

Triple-negative breast cancer: current state of the art.

Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S.

Tumori. 2010 Nov-Dec;96(6):875-88. Review.

Items per page

Supplemental Content

Write to the Help Desk